In primary CLL cells in suspension culture, TAK-659 treatment resulted in a dose-dependent reduction in the phosphorylation of SykTyr525, Btk, NFκB, ERK1/2 and STAT3 after BCR stimulation (Figure 2C and 2D). The gene discussed is MAPK3; the disease is B-cell chronic lymphocytic leukemia.